AGP Executive Report
Last update: 28 minutes agoHepatitis B Breakthrough: Researchers say a “functional cure” for chronic hepatitis B may finally be within reach, noting that while a vaccine exists, today’s antivirals can suppress but not eliminate the virus—millions in Europe (including Liechtenstein) are living with chronic infection. Patient Safety & Supply Chains: Dental manufacturer Ivoclar is rolling out a verification program to help clinics avoid counterfeit and gray-market dental products, warning that unofficial supply can mean expired or degraded materials and unsafe treatment outcomes. COVID-19 Protection Update: Pfizer-BioNTech received EU marketing authorization for a 2026–2027 COVID-19 vaccine adapted to the XFG variant, approved for people 6 months and older across EU states plus Iceland, Liechtenstein and Norway. Cancer Drug Deal: IMPACT Therapeutics and Pharmanovia signed an exclusive licensing partnership for senaparib across Europe and other regions including Liechtenstein, aiming at 1L maintenance therapy for advanced ovarian cancers, with regulatory review expected to progress in 2026. Local Health Governance: A Malta political controversy is spilling into government staffing, with a former insider reportedly recruited as a consultant at the Economy Ministry after a parliamentary privilege complaint tied to threats against an opposition MP.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
